Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Erythrocytes01:27

Disorders of Erythrocytes

1.0K
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
1.0K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.3K
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

15
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
15
Alternative RNA Splicing02:18

Alternative RNA Splicing

21.6K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
21.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Protein Profile of Multiple Myeloma-Derived Extracellular Vesicles for the Discovery of Novel Myeloma-Related Biomarkers.

Cancer science·2026
Same author

Rethinking On-Target Off-Tumor Toxicity as a Hematopoietic Continuum.

European journal of haematology·2026
Same author

Mechanisms of post-transplant AML relapse and therapeutic implications.

Bone marrow transplantation·2026
Same author

Ferroptosis in Lymphoproliferative Disorders.

Cells·2026
Same author

Bridging Randomized Trial Efficacy and Real-World Effectiveness in Multiple Myeloma: Integrating Clinical Trials and Real-World Evidence for Individualized Care.

European journal of haematology·2026
Same author

Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience.

British journal of haematology·2026

Related Experiment Video

Updated: Aug 9, 2025

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.8K

Myelodysplastic syndromes with ring sideroblasts.

Antonella Bruzzese1, Ernesto Vigna1, Enrica Antonia Martino1

  • 1Hematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy.

Hematological Oncology
|February 16, 2023
PubMed
Summary

Myelodysplastic syndromes (MDS) with SF3B1 mutation are linked to ineffective red blood cell production. Luspatercept shows promise in treating anemia in MDS patients by improving red blood cell maturation.

Keywords:
MDS-RSSF3B1luspaterceptmyelodysplastic syndromesring sideroblasts

More Related Videos

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

11.7K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.3K

Related Experiment Videos

Last Updated: Aug 9, 2025

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.8K
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

11.7K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.3K

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • Myelodysplastic syndromes (MDS) are bone marrow disorders causing ineffective blood cell production.
  • The World Health Organization (WHO) now classifies MDS with SF3B1 mutation due to its strong association with MDS with ring sideroblasts.
  • SF3B1 mutations disrupt gene expression, impacting hematopoietic stem and progenitor cells, particularly iron metabolism (PPOX, ABCB7) and TGF-β signaling.

Purpose of the Study:

  • To explore the genotype-phenotype correlation in MDS with SF3B1 mutation.
  • To review the mechanism of action and efficacy of luspatercept in treating MDS-related anemia.
  • To identify future research directions for luspatercept in MDS treatment.

Main Methods:

  • Review of scientific literature on MDS, SF3B1 mutations, and luspatercept.
  • Analysis of data from the phase III MEDALIST trial.
  • Exploration of molecular pathways involved in MDS pathogenesis and treatment response.

Main Results:

  • SF3B1 mutations are central to MDS pathogenesis, affecting iron metabolism and TGF-β signaling.
  • Luspatercept, a TGF-β superfamily inhibitor, demonstrated efficacy in treating anemia in MDS patients in the MEDALIST trial.
  • Luspatercept promotes erythroid maturation by modulating SMAD signaling.

Conclusions:

  • Luspatercept is a promising therapeutic agent for anemia in MDS patients with SF3B1 mutations.
  • Further research is needed to understand treatment response predictors, combination therapies, and luspatercept's role in treatment-naïve MDS.